Drug Profile
Roledumab - LFB Biotechnologies
Alternative Names: ADNC; Anti-D monoclonal antibody - LFB; Anti-RhD-antibody; Anti-Rhesus-D-monoclonal-antibody-LFB; Dmatria; LFB-R593; Monoclonal-anti-DLatest Information Update: 27 Apr 2022
Price :
$50
*
At a glance
- Originator LFB Biotechnologies
- Class Monoclonal antibodies
- Mechanism of Action Rh-Hr blood group system inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Haemolytic disease of newborn
Most Recent Events
- 27 Apr 2022 No development reported - Phase-II/III for Haemolytic disease of newborn (Prevention) in France (IM)
- 22 Aug 2019 No development reported - Phase-II for Haemolytic disease of newborn (Prevention) in Germany (IM)
- 22 Aug 2019 No development reported - Phase-II for Haemolytic disease of newborn (Prevention) in Germany (IV)